Unlabelled: Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen. Comprehensive workup ruled out other causes, leading to a diagnosis of drug-induced hepatotoxicity. Discontinuation of nebivolol resulted in normalization of liver enzymes. This case underscores the importance of monitoring liver function during beta-blocker therapy, particularly with nebivolol.
Learning Points: Nebivolol, despite its favourable safety profile, can lead to significant liver injury.Clinicians should remain vigilant and consider routine liver function monitoring in patients prescribed nebivolol, particularly if they present with nonspecific symptoms or abnormal liver enzyme tests.Early recognition and prompt discontinuation of the offending agent are crucial in preventing severe outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542944 | PMC |
| http://dx.doi.org/10.12890/2024_004866 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Use of sacituzumab govitecan in frail patients with skin disease.].
Recenti Prog Med
November 2024
UO Oncologia Medica clinica la Maddalena, Palermo.
The clinical case described concerns a 53-year-old patient with triple-negative disease, metastatic to the skin, fragile, not due to comorbidities, but due to toxicities from previous antiblastic treatments. The major toxicities reported, even previously, were inherent to bone marrow function, with prolonged neutropenia, despite the use of granulocyte growth factor (GCSF). The patient has no family history of breast cancer and does not have a mutation in the BRCA1/2 genes.
View Article and Find Full Text PDFNebivolol-Induced Hepatoxicity: A Case Report.
Eur J Case Rep Intern Med
October 2024
Department of Gastroenterology, University of Balamand, Beirut, Lebanon.
Unlabelled: Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen.
View Article and Find Full Text PDFβ-Blockers and Asthma: Surprising findings from the FAERS database.
Respir Med
November 2024
Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Introduction: β-Blockers are essential for cardiovascular disease management but can induce respiratory issues, particularly with non-selective β-blockers. Their safety in asthmatic patients is debated.
Objective: This study investigates the link between different classes of β-blockers and the risk of asthma and asthma-like adverse events (AEs) using data from the Food and Drug Administration's Adverse Event Reporting System (FAERS).
Anti-hypertensive medications and erectile dysfunction: focus on β-blockers.
Endocrine
January 2025
Endocrinology Unit Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy.
Purpose: Although anti-hypertensive medications, including thiazides and β-blockers (BBs) in particular, have been suggested to cause erectile dysfunction (ED) their real contribution is still conflicting. The aim of this paper is to summarize available evidence providing an evidence-based critical analysis of the topic.
Methods: An overall comprehensive narrative review was performed using Medline, Embase and Cochrane search.
Physicians' attitudes toward beta-blockers for the treatment of hypertension in Italy, Poland, and Turkey.
J Clin Hypertens (Greenwich)
June 2024
MeSVA Department, University of L'Aquila, L'Aquila, Italy.
Despite substantial progress in understanding the complex pathophysiology, hypertension remains a serious public health challenge affecting over 1.2 billion adults aged 30-79 years worldwide. Appropriate knowledge of the different pharmaceutical classes of antihypertensive agents and an understanding of the characteristics of individual molecules are essential to optimize clinical outcomes in patients with hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!